Daneng Li
Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the Hepatobiliary Tumor program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope.
Dr. Li earned his undergraduate degree from The Ohio State University in Columbus, Ohio, graduating summa cum laude. He then went on to receive his medical doctorate from Weill Cornell Medical College in New York, before pursuing an internship and residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center. He then completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City.
Board certified in internal medicine and medical oncology, Dr. Li serves on several national committees focused on his specialty tumor types. He has authored several publications in the peer reviewed literature, and has presented his work both nationally and internationally.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstraZenecaTopic:HCCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Brooklyn ImmunoTherapeuticsTopic:HCCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AdageneTopic:HCCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:EisaiTopic:HCCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ExelixisTopic:HCCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenentechTopic:HCCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:IpsenTopic:Pancreas, NETDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MerckTopic:HCCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:QEDTopic:BTCDate added:03/17/2022Date updated:12/11/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ServierTopic:BTCDate added:03/17/2022Date updated:12/11/2024